Cargando…

Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era

Since 2004, multiple blockbuster drugs have been approved for men with metastatic prostate cancer. Nevertheless, it has been reported that no improvement in survival was observed between 2004 and 2009. Herein, we have analyzed the SEER database to assess the survival outcome of metastatic prostate c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Isaac E., Jang, Thomas L., Kim, Sinae, Lee, David Y., Kim, Daniel D., Singer, Eric A., Ghodoussipour, Saum, Stein, Mark N., Aron, Monish, Dall’Era, Marc A., Yi Kim, Isaac
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607264/ https://www.ncbi.nlm.nih.gov/pubmed/34713977 http://dx.doi.org/10.1002/cam4.4074

Ejemplares similares

Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations
por: Kim, Isaac E., et al.
Publicado: (2022)

Rational Second-Generation Antiandrogen Use in Prostate Cancer
por: Orme, Jacob J, et al.
Publicado: (2022)

The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype
por: Monda, Steven M., et al.
Publicado: (2023)

Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond
por: Srivastava, Arnav, et al.
Publicado: (2021)

Trends in active surveillance for very low‐risk prostate cancer: do guidelines influence modern practice?
por: Parikh, Rahul R., et al.
Publicado: (2017)

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
por: Besançon, Marjorie, et al.
Publicado: (2022)

Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial Carcinoma
por: Drobner, Jake C., et al.
Publicado: (2023)

Updates on enhanced recovery after surgery for radical cystectomy
por: Lee, Grace, et al.
Publicado: (2022)

Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy
por: Kim, Isaac Yi, et al.
Publicado: (2022)

GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance
por: Lee, Eugine, et al.
Publicado: (2019)

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
por: Wu, Meng, et al.
Publicado: (2023)

Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
por: Sun, Rui, et al.
Publicado: (2023)

Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer
por: Shah, Neel, et al.
Publicado: (2017)

Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
por: Kim, Isaac E., et al.
Publicado: (2019)

Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer
por: Yuh, Bertram E., et al.
Publicado: (2019)

The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer
por: Cahill, Ellen M., et al.
Publicado: (2022)

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
por: Verma, Shiv, et al.
Publicado: (2020)

Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments
por: Goldberg, Ilana P., et al.
Publicado: (2022)

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
por: Semenas, Julius, et al.
Publicado: (2013)

Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer
por: Nowakowska, Malgorzata K., et al.
Publicado: (2021)

Indications for and transitioning to secondary treatment while on active surveillance for prostate cancer
por: Glass, Allison S., et al.
Publicado: (2018)

Active Surveillance for Intermediate Risk Prostate Cancer
por: Dall'Era, Marc A., et al.
Publicado: (2016)

Defining the Optimal Management Strategy for Small Renal Masses
por: Dall’Era, Marc, et al.
Publicado: (2021)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

Acute lung injury following penile ischemia and reperfusion
por: Yip, Wesley, et al.
Publicado: (2018)

Patient-Centered Outcomes Research Institute (PCORI) multisite project to develop treatment decision aids for racial/ethnic minorities with lupus nephritis
por: Yazdany, Jinoos, et al.
Publicado: (2014)

Active Surveillance for Localized Prostate Cancer – Current Practices and Recommendations
por: Wu, Jennifer N., et al.
Publicado: (2010)

Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
por: Rice, Meghan A., et al.
Publicado: (2019)

Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives
por: Pinto, Francesco, et al.
Publicado: (2022)

Super active surveillance for low-risk prostate cancer | Opinion: No
por: Ghodoussipour, Saum, et al.
Publicado: (2019)

Leiomyoma of the testis: case report, review of literature, and discussing the role of contrast-enhanced ultrasound
por: Asanad, Kian, et al.
Publicado: (2020)

The Role of Salvage Radical Prostatectomy in Patients with Radiation-Resistant Prostate Cancer
por: Drobner, Jake, et al.
Publicado: (2023)

Active surveillance for prostate cancer
por: Dall’Era, Marc A., et al.
Publicado: (2018)

Intermittent, low-dose, antiandrogen monotherapy as an alternative therapeutic option for patients with positive surgical margins after radical prostatectomy
por: Choi, Kyung Hwa, et al.
Publicado: (2018)

A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
por: Welén, Karin, et al.
Publicado: (2022)

Editorial by Bendu K. Konneh, John T. Lafin and Aditya Bagrodia on pp. 341–342 of this issue: MicroRNA-371a-3p as a blood-based biomarker in testis cancer
por: Ahmadi, Hamed, et al.
Publicado: (2021)

Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era
por: LeMieux, Melissa H, et al.
Publicado: (2015)

Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
por: Patel, Aakash, et al.
Publicado: (2021)

Radical prostatectomy for high-risk prostate cancer | Opinion: NO
por: Ghodoussipour, Saum, et al.
Publicado: (2019)

Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution
por: Yegya-Raman, Nikhil, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a88fgevn4vevsuhhfpo37thfk2